Activation of toll-like receptor 2 promotes invasion by upregulating MMPS in glioma stem cells

American Journal of Translational Research

Volumn 7, Issue 3, 2015, Pages 607-615

  Wang, Fan ^a   Zhang, Peng ^a   Yang, Lang ^a   Yu, Xi ^a   Ye, Xianzhong ^a   Yang, Jing ^a   Qian, Cheng ^a   Zhang, Xia ^a   Cui, You Hong ^a   Bian, Xiu Wu ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Glioma stem cells; Invasion; Matrix metalloproteinases; Pam3CSK4; Toll like receptor 2

Indexed keywords

GELATINASE A; GELATINASE B; NESTIN; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; TOLL LIKE RECEPTOR 2; TRANSCRIPTION FACTOR SOX2;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; FEMALE; GENE SILENCING; GLIOBLASTOMA; GLIOMA CELL; IMMUNOFLUORESCENCE; MOUSE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

MUS;

EID: 84929998850     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. [1] Maes W, Van Gool SW. Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model. Cancer Immunol Immunother 2011; 60: 153-60.
2. [2] Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, La-combe D, Cairncross JG, Eisenhauer E, Miri-manoff RO; European Organisation for Res-earch and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.
3. [3] Nieder C, Grosu AL, Molls M. A comparison of treatment results for recurrent malignant gliomas. Cancer Treat Rev 2000; 26: 397-409.
4. [4] Chen DL, Ping YF, Yu SC, Chen JH, Yao XH, Jiang XF, Zhang HR, Wang QL, Bian XW. Dow-nregulating FPR restrains xenograft tumors by impairing the angiogenic potential and invasive capability of malignant glioma cells. Biochem Biophys Res Commun 2009; 381: 448-52.
5. [5] Yu SC, Ping YF, Yi L, Zhou ZH, Chen JH, Yao XH, Gao L, Wang JM, Bian XW. Isolation and characterization of cancer stem cells from a human glioblastoma cell line U87. Cancer Lett 2008; 265: 124-34.
6. [6] Zhou ZH, Ping YF, Yu SC, Yi L, Yao XH, Chen JH, Cui YH, Bian XW.A novel approach to the identification and enrichment of cancer stem cells from a cultured human glioma cell line. Cancer Lett 2009; 281: 92-9.
7. [7] Yu SC, Xiao HL, Jiang XF, Wang QL, Li Y, Yang XJ, Ping YF, Duan JJ, Jiang JY, Ye XZ, Xu SL, Xin YH, Yao XH, Chen JH, Chu WH, Sun W, Wang B, Wang JM, Zhang X, Bian XW. Connexin 43 reverses malignant phenotypes of glioma stem cells by modulating E-cadherin. Stem Cells 2012; 30: 108-20.
8. [8] Sampetrean O, Saya H. Characteristics of glioma stem cells. Brain Tumor Pathol 2013; 30: 209-14.
9. [9] Ye XZ, Xu SL, Xin YH, Yu SC, Ping YF, Chen L, Xiao HL, Wang B, Yi L, Wang QL, Jiang XF, Yang L, Zhang P, Qian C, Cui YH, Zhang X, Bian XW. Tumor-associated microglia/macrophages enhance the invasion of glioma stem cells via TGF-β1 signaling pathway. J Immunol 2012; 189: 444-53.
10. [10] Xie W, Wang Y, Huang Y, Yang H, Wang J, Hu Z. Toll-like receptor 2 mediates invasion via activating NF-kappaB in MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun 2009; 379: 1027-32.
11. [11] Vinnakota K, Hu F, Ku MC, Georgieva PB, Szu-lzewsky F, Pohlmann A, Waiczies S, Waiczies H, Niendorf T, Lehnardt S, Hanisch UK, Synowitz M, Markovic D, Wolf SA, Glass R, Kettenmann H. Toll-like receptor 2 mediates microglia/brain macrophage MT1-MMP expression and glioma expansion. Neuro Oncol 2013; 15: 1457-68.
12. [12] Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
13. [13] Suvà ML, Rheinbay E, Gillespie SM, Patel AP, Wakimoto H, Rabkin SD, Riggi N, Chi AS, Cahill DP, Nahed BV, Curry WT, Martuza RL, Rivera MN, Rossetti N, Kasif S, Beik S, Kadri S, Tirosh I, Wortman I, Shalek AK, Rozenblatt-Rosen O, Regev A, Louis DN, Bernstein BE. Recons-tructing and reprogramming the tumor-propagating potential of glioblastoma stem cells. Cell 2014; 157: 580-94.
14. [14] Kim ES, Kim MS, Moon A. TGF-beta-induced upregulation of MMP-2 and MMP-9 depends on p38 MAPK, but not ERK signaling in MCF10A human breast epithelial cells. Int J Oncol 2004; 25: 1375-82.
15. [15] Maes W, Van Gool SW. Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model. Cancer Immunol Immunother 2011; 60: 153-60.
16. [16] Holland EC. Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet 2001; 2: 120-9.
17. [17] Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 2008; 27: 218-24.
18. [18] Garay RP, Viens P, Bauer J, Normier G, Bardou M, Jeannin JF, Chiavaroli C. Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help. Eur J Pharmacol 2007; 563: 1-17.
19. [19] Yang H, Wang B, Yan J, Wang T, Zhou XN, Wen HY, Zhu XM. Toll-like receptor 2 promotes invasion by SGC-7901 human gastric carcinoma cells and is associated with gastric carcinoma metastasis. Ann Clin Lab Sci 2014; 44: 158-66.
20. [20] Guo H, Chen Y, Hu X, Qian G, Ge S, Zhang J. The regulation of Toll-like receptor 2 by miR-143 suppresses the invasion and migration of a subset of human colorectal carcinoma cells. Mol Cancer 2013; 12: 77.
21. [21] Page K, Ledford JR, Zhou P, Wills-Karp M. A TLR2 agonist in German cockroach frass activates MMP-9 release and is protective against allergic inflammation in mice. J Immunol 2009; 183: 3400-8.
22. [22] Hu F, Ku MC, Markovic D, A Dzaye OD, Lehnardt S, Synowitz M, Wolf SA, Kettenmann H. Glioma-associated microglial MMP9 expression is upregulated by TLR2 signaling and sensitive to minocycline. Int J Cancer 2014; 135: 2569-78.
23. [23] Yang L, Ping YF, Yu X, Qian F, Guo ZJ, Qian C, Cui YH, Bian XW. Gastric cancer stem cells possess higher capability of invasion and metastasis in association with a mesenchymal transition phenotype. Cancer Lett 2011; 310: 46-52.
24. [24] Shi Y, Chen C, Zhang X, Liu Q, Xu JL, Zhang HR, Yao XH, Jiang T, He ZC, Ren Y, Cui W, Xu C, Liu L, Cui YH, Yu SZ, Ping YF, Bian XW. Primate-specific miR-663 functions as a tumor suppressor by targeting PIK3CD and predicts the prognosis of human glioblastoma. Clin Cancer Res 2014; 20: 1803-13.